Home / Featured

Fixed-Duration and De-escalated Therapy

Doing less on purpose: fixed-duration regimens tested against treatment until progression, risk-adapted observation, and the evidence needed before an established therapy can safely be shortened or withheld.

9 articles in this topic

  • October 12, 2026Journal of Clinical OncologyRT CHARM, Alliance A221505 (NCT03414970)

    Hypofractionated Postmastectomy Radiation Is Non-Inferior for 24-Month Reconstruction Complications: The RT CHARM Randomized Trial

    RT CHARM (Alliance A221505) randomized 898 patients to conventional postmastectomy radiation (50 Gy in 25 fractions) or hypofractionated radiation (42.56 Gy in 16 fractions) after mastectomy with planned or completed breast reconstruction. Among 825 evaluable patients, the 24-month reconstruction complication rate was 12.3% with hypofractionation vs 10.2% with conventional radiation (difference −2.1%, 95% CI −6.5% to 2.2%), meeting the prespecified 10% non-inferiority margin (p = 0.0001).

  • August 20, 2026Journal of Clinical OncologyEA1181 (CompassHER2 pCR, single-arm), NCT04266249

    De-escalated Taxane Plus Trastuzumab and Pertuzumab Achieves 43.8% Pathologic Complete Response in HER2-Positive Breast Cancer, Far Higher in ER-Negative Than ER-Positive Disease: EA1181 Secondary Analyses

    EA1181 (CompassHER2 pCR) is a single-arm trial of de-escalated neoadjuvant therapy in Stage II–IIIa HER2-positive breast cancer: 12 weeks of a single taxane (paclitaxel, docetaxel or nab-paclitaxel) plus trastuzumab and pertuzumab (THP). In this secondary analysis of 2,141 evaluable patients, the overall pathologic complete response (pCR) rate was 43.8% (95% CI, 41.6%–45.9%).

  • July 24, 2026Annals of OncologyNCT01272037

    Low Ovarian Reserve Predicts No Chemotherapy Benefit in Node-Positive, HR-Positive Breast Cancer

    A prespecified biomarker analysis of the phase 3 RxPONDER (SWOG S1007) trial finds that serum anti-Müllerian hormone (AMH), a marker of ovarian reserve, identifies which women under 55 with hormone receptor-positive, HER2-negative, node-positive breast cancer actually benefit from adding chemotherapy to endocrine therapy — outperforming menopausal status and age as a predictor.

  • May 28, 2026Annals of OncologyNCT02308085

    Pregnancy After Interrupting Endocrine Therapy Shows No Excess Breast Cancer Risk at 6 Years

    Updated results from the prospective, single-arm POSITIVE trial — now with a median follow-up of 71 months, up from 41 months at the original analysis — found no increase in breast cancer recurrence risk among young women with hormone receptor-positive disease who paused adjuvant endocrine therapy to attempt pregnancy.

  • August 20, 2026JAMA Oncology

    Meningioma Diagnoses Nearly Doubled in Denmark Over 14 Years — But Most Surveillance Scans Never Led to Treatment

    A nationwide Danish registry study of 8,134 patients found that age- and sex-standardized meningioma incidence nearly doubled between 2010 and 2023, rising from 6.4 to 12.6 cases per 100,000 person-years, while the proportion of diagnosed patients who ultimately received surgery fell from 43.9% to 23.4%.

  • August 20, 2026JAMA Oncology

    Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

    A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

  • August 10, 2026Journal of Clinical OncologyNRG Oncology RTOG 0539 (NCT00895622)

    10-Year Data Validate Risk-Adapted Meningioma Strategy: Observation, Then Selective Radiotherapy

    Long-term follow-up (median exceeding 10 years) of NRG Oncology RTOG 0539 validates a risk-adapted meningioma strategy: observation after gross total or subtotal resection for low-risk (WHO grade 1) disease, and radiotherapy for intermediate- and high-risk disease.

  • July 16, 2026New England Journal of MedicineENDURANCE (ECOG-ACRIN E1A11) maintenance randomization (NCT01863550)

    Indefinite Lenalidomide Maintenance Fails to Beat 2-Year Fixed Duration in Myeloma

    Randomized phase 3 comparison, from the maintenance ("R2") randomization of the ECOG-ACRIN ENDURANCE (E1A11) trial, of indefinite-duration versus fixed 2-year lenalidomide maintenance in 516 standard-risk multiple myeloma patients who did not undergo up-front autologous stem-cell transplantation.

  • March 12, 2026New England Journal of MedicineCLL17 (NCT04608318)

    Fixed-Duration Therapy Matches Continuous Treatment in Previously Untreated Chronic Lymphocytic Leukemia: The CLL17 Trial

    Phase 3 randomized trial of 909 patients with previously untreated CLL across 174 sites in 13 countries

Cancer types covered: Breast Cancer · Brain Cancer · Lung Cancer · Melanoma · Pancreatic Cancer · Ovarian Cancer · Kidney Cancer · Bladder Cancer · Leukemia · Lymphoma · Multiple Myeloma · Head and Neck Cancer · Sarcoma · Prostate Cancer · Colorectal Cancer · Gastric Cancer · Esophageal Cancer · Hepatocellular Carcinoma · Anal Cancer · Endometrial Cancer · Cervical Cancer · Biliary Tract Cancer · AL Amyloidosis